Overall, in β-catenin<sup>S33Y</sup>-mutated HCC, OXCT1 activation leads to metabolic reprogramming of ketone bodies, resulting in resistance to ketogenic therapy and promoting metastasis. This evidence concerns the gene OXCT1 and hepatocellular carcinoma.